Trevi Therapeutics, Inc.

NasdaqGM TRVI

Trevi Therapeutics, Inc. Share Price on February 05, 2025: USD 4.21

Trevi Therapeutics, Inc. Share Price is USD 4.21 on February 05, 2025, a 200.71% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Trevi Therapeutics, Inc. 52-week high Share Price is USD 4.59 on January 03, 2025, which is 9.03% above the current Share Price.
Trevi Therapeutics, Inc. 52-week low Share Price is USD 1.46 on February 06, 2024, which is -65.32% below the current Share Price.
Trevi Therapeutics, Inc. average Share Price for the last 52 weeks is USD 3.05.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqGM: TRVI

Trevi Therapeutics, Inc.

CEO	Ms. Jennifer L. Good
IPO Date	May 7, 2019
Location	United States
Headquarters	195 Church Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years